Pharos I Bio to Participate in BIO USA, Pursuing Global Technology Transfer

Plans to Actively Promote the Potential and Possibilities of K-Anticancer New Drugs

Pharos I Bio, a company specializing in AI-driven innovative drug development, announced on June 9 that it will participate in the 2025 BIO International Convention (BIO USA), which will be held in Boston, USA, from June 16 to 19 (local time).

Reference image. Pharos I Bio

BIO USA is the world's largest pharmaceutical and biotechnology conference, held annually by the Biotechnology Innovation Organization in major bio industry hubs in the United States. Last year, nearly 20,000 industry professionals from over 70 countries attended, and more than 60,000 partnering meetings took place.

Pharos I Bio plans to showcase its research achievements on next-generation acute myeloid leukemia (AML) therapy 'PHI-101' and refractory solid tumor therapy 'PHI-501', and to actively seek global collaboration opportunities.

PHI-101, the company's lead pipeline candidate, is an innovative anticancer drug candidate identified through its proprietary AI drug discovery platform, Chemiverse. It is known as a next-generation AML therapy targeting various resistant mutations of the FLT3 protein. PHI-101 offers a new treatment option for patients with relapsed or refractory AML, and has demonstrated high therapeutic efficacy in global Phase 1 clinical trials, as well as AI-predicted cardiac safety in non-clinical studies.

PHI-501, which has entered Phase 1 clinical trials, is a therapy for refractory solid tumors. In recent preclinical studies, it showed outstanding therapeutic effects in refractory lung cancer, malignant melanoma, and refractory colorectal cancer, all of which have limited existing treatment options. In March, Pharos I Bio submitted a Phase 1 IND (Investigational New Drug application) for PHI-501 to the Ministry of Food and Drug Safety, and is actively pursuing entry into the high-value, 40 trillion won solid tumor anticancer drug market.

Yoon Junghyuk, CEO of Pharos I Bio, stated, "We plan to actively promote the potential and possibilities of PHI-101 and PHI-501 as next-generation K-anticancer drugs to global pharmaceutical and biotechnology companies. By working closely with a variety of global partners, we will do our utmost to accelerate the development of innovative AI-driven drugs and provide new treatment options for patients with rare and intractable diseases worldwide."

Meanwhile, Pharos I Bio, which was listed in July 2023, is an AI-based innovative drug development company seeking various opportunities to enter the global market. Its lead pipeline candidates, PHI-101 and PHI-501, have been designated as orphan drugs (ODD) by the U.S. Food and Drug Administration (FDA).

This content was produced with the assistance of AI translation services.